Phase 3 THOR study: Results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selective fibroblast growth factor receptor alterations
Currently, immune checkpoint inhibitors (ICIs) are widely used as first-line therapy for patients with metastatic urothelial carcinoma who are ineligible for platinum-based therapy or who have failed first-line platinum-based chemotherapy. However, only 30% of patients receive subsequent anti-cancer treatments after discontinuing ICI. Several genomic studies of metastatic urothelial carcinoma have shown FGFR2/3 alterations in 20% of patients, and erdafitinib has demonstrated clinical benefit in patients with disease progression after platinum-based chemotherapy.
ORCHID Trial Shows Potential for Olaparib in Patients with Metastatic Renal Cell Carcinoma Carrying Mutations in BAP1 or Other DNA Repair Genes
In the interim analysis of the ORCHID study, metastatic renal cell carcinoma patients with BAP1 or other DNA repair gene mutations benefited from olaparib, which were presented at the 2023 Kidney Cancer Research Summit.
The First Treatment-switching by Monitoring Plasma ESR1 Mutations with circulating tumor DNA (ctDNA) Demonstrated Promising Clinical Benefit in the Phase III PADA-1 Study
Abstract: ASCO 2023 annual meeting updated with latest data from PADA-1 study, switching aromatase inhibitor (AI) to fulvestrant in case of rising ESR1 mutations by longitudinal ctDNA monitoring, showing progression-free survival1 (PFS1) and PFS2 significantly improved.
TALAPRO-2: Phase III study of talazoparib plus enzalutamide as first-line treatment for mCRPC patients harboring homologous recombination repair gene alterations
The TALAPRO-2 study demonstrated a statistically improvement of rPFS with talazoparib and enzalutamide combination in HRR gene-mutated mCRPC.
Efficacy and safety of a novel FAK/ALK/ROS1 inhibitor, APG-2449, demonstrated antitumor activity in NSCLC patients who are resistant to 2nd generation ALK-TKI
APG-2449 is a novel, orally active FAK inhibitor and an ALK/ROS1 tyrosine kinase inhibitor (TKI) that showed a favorable safety profile and antitumor efficacy in patients with NSCLC, according to results from the poster at the 2023 ASCO Annual Meeting.
Yuxiang Ma, Hongyun Zhao, et al. Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 9015-9015.
Subgroup analysis of CodeBreak 200 assessed baseline biomarker status and efficacy of sotorasib and docetaxel
Results of phase 3 CodeBreak 200 trial were presented at the 2023 ASCO Annual Meeting. Subgroup analyzes of biomarkers and efficacy indicated superiority of sotorasib over docetaxel.
Ferdinandos Skoulidis et al., 10.1200/JCO.2023.41.16_suppl.9008 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 9008-9008, ASCO 2023 Annual Meeting.
Vorasidenib for low-grade glioma patients with an IDH1/2 mutation: results from the phase III INDIGO trial
The current standard therapies for IDH1/2-mutant low-grade glioma are surgery, radiotherapy followed by temozolomide (TMZ) or procarbazine + lomustine + vincristine (PCV). However, these treatments are not curative.
INDIGO: a phase 3 global, randomized, double-blinded study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation (Slide presentation in ASCO 2023)
Efficacy and safety of anti-EGFR/HER3 bispecific ADC: BL-B01D1 demonstrated in patients with EGFR+ NSCLC and other advanced solid tumors
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), demonstrate antitumor activity and tolerability in several types of advanced solid tumors, especially in EGFR+ NSCLC, according to result from a phase 1 study presented at the 2023 ASCO Annual Meeting.